MedTrace Logo

Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck

NCT03132038 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2022-01-11

No results posted yet for this study

Summary

INDICATION:

Patients with recurrent and/or metastatic salivary glands carcinoma who have progressed during the 6 months period before entering the study and who are eligible for nivolumab monotherapy.

Conditions

Interventions

DRUG

Nivolumab

3 mg/kg, every two weeks, during a maximum of one year

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Jérôme FAYETTE, MD · Léon Bérard Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-24
Primary Completion
2019-01-01
Completion
2021-10-20

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03132038 on ClinicalTrials.gov